In vitro and in vivo properties of synthetic inhibitors of thrombin: recent advances.
Okamoto
S
S
Kobe Research Projects on Thrombosis and Haemostasis, Japan.
Wanaka
K
K
Hijikata-Okunomiya
A
A
D000818:Animals; D000991:Antithrombins / Q000737:chemistry / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives; D015195:Drug Design; D006801:Humans; D010875:Pipecolic Acids / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors*; D015912:Thrombolytic Therapy; D014106:Tosylarginine Methyl Ester / Q000737:chemistry
D000991:Antithrombins; D010875:Pipecolic Acids; D011480:Protease Inhibitors; D013449:Sulfonamides; D014106:Tosylarginine Methyl Ester; D001120:Arginine; D013917:Thrombin; C031942:argatroban